|
1
|
Dombret H and Gardin C: An update of
current treatments for adult acute myeloid leukemia. Blood.
127:53–61. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Estey EH: Acute myeloid leukemia: 2014
update on risk-stratification and management. Am J Hematol.
89:1063–1081. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen Y, Song YX and Wang ZN: The
microRNA-148/152 family: Multi-faceted players. Mol Cancer.
12:432013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang XX, Zhang R and Li Y: Expression of
the miR-148/152 family in acute myeloid leukemia and its clinical
significance. Med Sci Monit. 23:4768–4778. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Islam M, Mohamed Z and Assenov Y:
Differential analysis of genetic, epigenetic, and cytogenetic
abnormalities in AML. Int J Genomics. 2017:29136482017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kameda T, Shide K and Shimoda K: Genetic
and epigenetic abnormalities in myeloproliferative neoplasms.
Rinsho Ketsueki. 56:614–622. 2015.(In Japanese). PubMed/NCBI
|
|
7
|
Tamamyan G, Kadia T, Ravandi F, Borthakur
G, Cortes J, Jabbour E, Daver N, Ohanian M, Kantarjian H and
Konopleva M: Frontline treatment of acute myeloid leukemia in
adults. Crit Rev Oncol Hematol. 110:20–34. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Furukawa Y, Sutheesophon K, Wada T,
Nishimura M, Saito Y, Ishii H and Furukawa Y: Methylation silencing
of the Apaf-1 gene in acute leukemia. Mol Cancer Res. 3:325–334.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu SH, Zheng CP, Xu J, Cai XP and Shi YJ:
Expression of DNMT gene in bone marrow of patients with acute
myelogenous leukemia and its significance. Zhongguo Shi Yan Xue Ye
Xue Za Zhi. 20:1063–1065. 2012.(In Chinese). PubMed/NCBI
|
|
10
|
Long XR, He Y, Huang C and Li J:
MicroRNA-148a is silenced by hypermethylation and interacts with
DNA methyltransferase 1 in hepatocellular carcinogenesis. Int J
Oncol. 44:1915–1922. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sun J, Song Y, Wang Z, Wang G, Gao P, Chen
X, Gao Z and Xu H: Clinical significance of promoter region
hypermethylation of microRNA-148a in gastrointestinal cancers. Onco
Targets Ther. 7:853–863. 2014.PubMed/NCBI
|
|
12
|
Zhan Q, Fang Y, Deng X, Chen H, Jin J, Lu
X, Peng C, Li H and Shen B: The interplay between miR-148a and
DNMT1 might be exploited for pancreatic cancer therapy. Cancer
Invest. 33:267–275. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhu A, Xia J, Zuo J, Jin S, Zhou H, Yao L,
Huang H and Han Z: MicroRNA-148a is silenced by hypermethylation
and interacts with DNA methyltransferase 1 in gastric cancer. Med
Oncol. 29:2701–2709. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bennett JM, Catovsky D, Daniel MT,
Flandrin G, Galton DA, Gralnick HR and Sultan C: Proposed revised
criteria for the classification of acute myeloid leukemia. A report
of the French-American-British Cooperative Group. Ann Intern Med.
103:620–635. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wandt H, Haferlach T, Thiede C and
Ehninger G: WHO classification of myeloid neoplasms and leukemia.
Blood. 115:748–750. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Schmittgen,
Analysis of relative gene expression data using real-time
quantitative PCR and the 2(-Delta Delta C(T)) method. Methods.
25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Butrym A, Rybka J, Baczyńska D, Tukiendorf
A, Kuliczkowski K and Mazur G: Low expression of microRNA-204
(miR-204) is associated with poor clinical outcome of acute myeloid
leukemia (AML) patients. J Exp Clin Cancer Res. 34:682015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shibayama Y, Kondo T, Ohya H, Fujisawa S,
Teshima T and Iseki K: Upregulation of microRNA-126-5p is
associated with drug resistance to cytarabine and poor prognosis in
AML patients. Oncol Rep. 33:2176–2182. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ajdarkosh H, Dadpay M, Yahaghi E, Pirzaman
ER, Fayyaz AF, Darian EK and Mokarizadeh A: Decrease expression and
clinicopathological significance of miR-148a with poor survival in
hepatocellular carcinoma tissues. Diagn Pathol. 10:1352015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hibino Y, Sakamoto N, Naito Y, Goto K, Oo
HZ, Sentani K, Hinoi T, Ohdan H, Oue N and Yasui W: Significance of
miR-148a in Colorectal Neoplasia: Downregulation of miR-148a
contributes to the carcinogenesis and cell invasion of colorectal
cancer. Pathobiology. 82:233–241. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li HP, Huang HY, Lai YR, Huang JX, Chang
KP, Hsueh C and Chang YS: Silencing of miRNA-148a by
hypermethylation activates the integrin-mediated signaling pathway
in nasopharyngeal carcinoma. Oncotarget. 5:7610–7624. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li L, Chen YY, Li SQ, Huang C and Qin YZ:
Expression of miR-148/152 family as potential biomarkers in
non-small-cell lung cancer. Med Sci Monit. 21:1155–1161. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sakamoto N, Naito Y, Oue N, Sentani K,
Uraoka N, Zarni Oo H, Yanagihara K, Aoyagi K, Sasaki H and Yasui W:
MicroRNA-148a is downregulated in gastric cancer, targets MMP7, and
indicates tumor invasiveness and poor prognosis. Cancer Sci.
105:236–243. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tian Y, Wei W, Li L and Yang R:
Down-regulation of miR-148a promotes metastasis by DNA methylation
and is associated with prognosis of skin cancer by targeting TGIF2.
Med Sci Monit. 21:3798–3805. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim J, Zhang Y, Skalski M, Hayes J, Kefas
B, Schiff D, Purow B, Parsons S, Lawler S and Abounader R:
microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to
regulate EGFR and apoptosis in glioblastoma. Cancer Res.
74:1541–1553. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yuan K, Lian Z, Sun B, Clayton MM, Ng IO
and Feitelson MA: Role of miR-148a in hepatitis B associated
hepatocellular carcinoma. PLoS One. 7:e353312012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ferreira HJ, Heyn H, Moutinho C and
Esteller M: CpG island hypermethylation-associated silencing of
small nucleolar RNAs in human cancer. RNA Biol. 9:881–890. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Aprelikova O, Palla J, Hibler B, Yu X,
Greer YE, Yi M, Stephens R, Maxwell GL, Jazaeri A, Risinger JI, et
al: Silencing of miR-148a in cancer-associated fibroblasts results
in WNT10B-mediated stimulation of tumor cell motility. Oncogene.
32:3246–3253. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Girault I, Tozlu S, Lidereau R and Bièche
I: Expression analysis of DNA methyltransferases 1, 3A, and 3B in
sporadic breast carcinomas. Clin Cancer Res. 9:4415–4422.
2003.PubMed/NCBI
|
|
30
|
Jin F, Dowdy SC, Xiong Y, Eberhardt NL,
Podratz KC and Jiang SW: Up-regulation of DNA methyltransferase 3B
expression in endometrial cancers. Gynecol Oncol. 96:531–538. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu Q, Jiang Y, Yin Y, Li Q, He J, Jing Y,
Qi YT, Xu Q, Li W, Lu B, et al: A regulatory circuit of
miR-148a/152 and DNMT1 in modulating cell transformation and tumor
angiogenesis through IGF-IR and IRS1. J Mol Cell Biol. 5:3–13.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pan W, Zhu S, Yuan M, Cui H, Wang L, Luo
X, Li J, Zhou H, Tang Y and Shen N: MicroRNA-21 and microRNA-148a
contribute to DNA hypomethylation in lupus CD4+ T cells by directly
and indirectly targeting DNA methyltransferase 1. J Immunol.
184:6773–6781. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhou X, Zhao F, Wang ZN, Song YX, Chang H,
Chiang Y and Xu HM: Altered expression of miR-152 and miR-148a in
ovarian cancer is related to cell proliferation. Oncol Rep.
27:447–454. 2012.PubMed/NCBI
|
|
34
|
Lombard AP, Mooso BA, Libertini SJ, Lim
RM, Nakagawa RM, Vidallo KD, Costanzo NC, Ghosh PM and Mudryj M:
miR-148a dependent apoptosis of bladder cancer cells is mediated in
part by the epigenetic modifier DNMT1. Mol Carcinog. 55:757–767.
2015. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang H, Li Y, Huang Q, Ren X, Hu H, Sheng
H and Lai M: MiR-148a promotes apoptosis by targeting Bcl-2 in
colorectal cancer. Cell Death Differ. 18:1702–1710. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fujita Y, Kojima K, Ohhashi R, Hamada N,
Nozawa Y, Kitamoto A, Sato A, Kondo S, Kojima T, Deguchi T and Ito
M: MiR-148a attenuates paclitaxel resistance of hormone-refractory,
drug-resistant prostate cancer PC3 cells by regulating MSK1
expression. J Biol Chem. 285:19076–8417. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hummel R, Watson DI, Smith C, Kist J,
Michael MZ, Haier J and Hussey DJ: Mir-148a improves response to
chemotherapy in sensitive and resistant oesophageal adenocarcinoma
and squamous cell carcinoma cells. J Gastrointest Surg. 15:429–438.
2011. View Article : Google Scholar : PubMed/NCBI
|
